Abstract library

2020 results for "high grade tumors".
#2896 Comparative Genomic Analysis of High Grade Neuroendocrine Neoplasms across Diverse Organs
Introduction: Grade 3 neuroendocrine neoplasms (G3 NENs), if poorly differentiated, have a median survival of 10-19 months. Little is known regarding biologic differences between G3 NENs from different primary sites, most commonly GI and lung.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Thomas Yang Sun
#2935 Prior Surgical Resection and Ga-68-DOTANOC PET/CT Imaging-Based Parameters: Do These Impact Outcomes in Grade II Gastroentero-Pancreatic Neuroendocrine Tumors (GEP-NETs)
Introduction: Grade 2 GEP-NETs have inherent tumor heterogeneity seen with positive expression of somatostatin (SSTR) and glucose (GLUT) receptors. Prior surgical resection and imaging parameters on Ga-68 DOTANOC PET/C are well-established variable impacting prognosis in well-differentiated grade 1 NETs. Since the degree of differentiation is variable in Grade 2 NETs, these parameters have not been studied.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dr Ameya Puranik
#2763 Incidence and Outcome of Brain Metastasis in Patients Diagnosed with Neuroendocrine Neoplasm
Introduction: Brain metastases are rarely reported in patients with neuroendocrine carcinoma of non-lung origin and neuroendocrine tumors (NETs) of the gastroenteropancreatic or bronchopulmonary system.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: Dr Arooj Fatima
Authors: Fatima A, Zaidi S S A, ...
#2904 Prognosis and Management of Advanced Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors (G3 NETs): A NET-CONNECT Study Performed in Four Expert Centers
Introduction: G3 NETs are rare tumors with poorly defined prognosis and management.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Louis de Mestier
#2843 Metastatic Risk in Pancreatic Neuroendocrine Tumors: A 16-Year Experience from Bogotá, Colombia. A Series Cases
Introduction: Pancreatic neuroendocrine tumors (pNET) are rare, have a wide range of phenotypes, increase incidence in recent years; which represents a challenge in diagnosis, treatment, and follow-up
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Deyanira González Devia
#3012 Causes of Death Following Neuroendocrine Tumors Diagnosis: A United States Population-Based Analysis
Introduction: Neuroendocrine tumors (NET) are heterogeneous in terms of prognosis based on location, grade, and stage.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: DR Mohamad Sonbol
#2987 68Ga-DOTATOC PET/CT as Tool for Diagnosis and Decision-Making Process of Neuroendocrine Tumors
Introduction: Primary tumors in some patients with metastatic neuroendocrine tumors (NET) cannot be found by conventional imaging as CT, MRI and scintigraphy. 68Ga-DOTATOC PET/CT (68Ga-PET) appears to have superior sensitivity, specifity, and better resolution than 99mTC-octreotide SPECT/TC (SSTR scintigraphy) and can improve decision-making process, however its cost is higher, and its availability is limited.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Inmaculada Peiró Martínez
#2693 The Distinctive Character of Micro-Vasculature and Immune Cell Infiltration in Cystic Pancreatic Neuroendocrine Tumors
Introduction: Hypervascularity is main character of pancreatic neuroendocrine tumors (PanNETs), cystic PanNET (CPanNET) are unique type of PanNETs for which the microenvironment remains unknown.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Heli Gao
Authors: Gao H, ...
#2741 Histologic Grading of Neuroendocrine Tumors and Its Relationship of Survival
Introduction: Current classification divides NENs into neuroendocrine tumors (NETs) and neuroendocrine carcinoma (NEC). NENs at different anatomic sites require site-specific applications for the classification.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: student Sofija Vilisova
#2828 G3 Neuroendocrine Tumours and Carcinomas: Clinicopathological Features for Distinct Entities
Introduction: The 2019 WHO subclassified the grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) into neuroendocrine carcinoma (NEC) or tumors (G3 NET). Yet, few data exist on clinical and treatment profiles for G3 NET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: MD Rodrigo G Taboada